Table 1 Baseline characteristics of the overall population and by tertiles of intact fibroblast growth factor 23 (iFGF23).
|  | Overall (n = 150) | iFGF23 < 35.2 pg/mL (n = 50) | iFGF23 35.2–50.9 pg/mL (n = 50) | iFGF23 > 50.9 pg/mL (n = 50) | p value (trend) |
|---|---|---|---|---|---|
Age, years | 65 (54–74) | 63 (54–72) | 68 (54–76) | 67 (57–75) | 0.325 |
Male, n (%) | 123 (82) | 39 (78) | 43 (86) | 41 (82) | 0.501 |
BMI, kg/m2 | 26.2 (23.9–29.8) | 26.0 (23.6–29.1) | 26.2 (24.5–26.7) | 26.8 (23.0-31.5) | 0.844 |
NYHA class | Â | Â | Â | Â | Â |
I | 39 (26) | 17 (34) | 13 (26) | 9 (18) | 0.152 |
II-III | 111 (74) | 33 (66) | 37 (74) | 41 (82) | Â |
Atrial fibrillation, n (%) | 21 (28) | 5 (10) | 12 (24) | 4 (8) | 0.036 |
Peak VO2/kg, mL/(kg·min) | 13.6 (10.8–18.0) | 17.1 (12.4–21.3) | 14.2 (11.1–18.4) | 12.3 (10.0-13.9) | < 0.001 |
LVEF, % | 32 (27–38) | 35 (30–39) | 35 (28–40) | 30 (25–38) | 0.014 |
LVMI, g/m2 | 129 (112–157) | 123 (109–143) | 132 (120–164) | 137 (115–178) | 0.103 |
PAPs, mmHg | 35 (29–40) | 32 (29–38) | 35 (29–40) | 36 (30–43) | 0.102 |
E/e’ | 12 (8–16) | 9 (7–12) | 13 (10–16) | 13 (7–18) | 0.089 |
Haemoglobin (g/dL) | 13.6 (1.5) | 13.9 (1.1) | 13.4 (1.6) | 13.7 (1.7) | 0.335 |
eGFR, mL/min/1.73 m2 | 73 ± 24 | 86 ± 20 | 75 ± 20 | 59 ± 23 | < 0.001 |
PTH, pg/mL | 19.6 (14.3–27.9) | 18.4 (12.3–25.4) | 17.8 (13.2–25.1) | 22.1 (16.7–35.0) | 0.003 |
Phosphate, mg/dL | 3.5 (3.0-4.1) | 3.4 (3.0-3.9) | 3.5 (3.0–4.0) | 3.7 (3.1–4.4) | 0.267 |
Calcium, mg/dL | 9.00 (8.75–9.20) | 9.00 (8.70–9.23) | 8.90 (8.70–9.10) | 9.10 (9.00-9.30) | 0.004 |
25-hydroxyvitamin D3, ng/mL | 16.26 (9.40-24.49) | 15.19 (7.60–21.50) | 20.53 (13.63–25.97) | 15.83 (9.09–25.44) | 0.078 |
NT-proBNP, ng/L | 953 (354–2024) | 686 (219–1349) | 822 (376–1567) | 1680 (635–3285) | 0.001 |
PRA, ng/mL/h | 1.31 (0.30–3.94) | 0.71 (0.20–2.40) | 1.13 (0.21–3.15) | 2.37 (0.75–7.44) | 0.003 |
Aldosterone, ng/dL | 137.8 (89.4-209.4) | 137.8 (98.9-190.7) | 105.5 (71.7-179.6) | 168.8 (91.4-322.2) | 0.027 |
Epinephrine, ng/L | 22 (10–52) | 18 (10–45) | 18 (10–51) | 27 (10–60) | 0.575 |
Norepinephrine, ng/L | 404 (283–595) | 388 (242–621) | 377 (241–523) | 510 (316–628) | 0.126 |
ACEi, n (%) | 92 (61) | 33 (66) | 30 (60) | 29 (58) | 0.557 |
ARBs, n (%) | 46 (31) | 17 (34) | 12 (24) | 17 (34) | 0.493 |
Beta blockers, n (%) | 130 (87) | 43 (86) | 44 (88) | 43 (86) | 0.708 |
MRAs, n (%) | 92 (61) | 30 (60) | 28 (56) | 34 (68) | 0.616 |
Diuretics, n (%) | 104 (69) | 31 (62) | 35 (70) | 38 (76) | 0.451 |